Cargando…
Novel Therapeutic Approaches in Inherited Neuropathies: A Systematic Review
The management of inherited neuropathies relies mostly on the treatment of symptoms. In recent years, a better understanding of the pathogenic mechanisms that underlie neuropathies has allowed for the development of disease-modifying therapies. Here, we systematically review the therapies that have...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10305260/ https://www.ncbi.nlm.nih.gov/pubmed/37376074 http://dx.doi.org/10.3390/pharmaceutics15061626 |
_version_ | 1785065691531968512 |
---|---|
author | Hustinx, Manon Shorrocks, Ann-Marie Servais, Laurent |
author_facet | Hustinx, Manon Shorrocks, Ann-Marie Servais, Laurent |
author_sort | Hustinx, Manon |
collection | PubMed |
description | The management of inherited neuropathies relies mostly on the treatment of symptoms. In recent years, a better understanding of the pathogenic mechanisms that underlie neuropathies has allowed for the development of disease-modifying therapies. Here, we systematically review the therapies that have emerged in this field over the last five years. An updated list of diseases with peripheral neuropathy as a clinical feature was created based on panels of genes used clinically to diagnose inherited neuropathy. This list was extended by an analysis of published data by the authors and verified by two experts. A comprehensive search for studies of human patients suffering from one of the diseases in our list yielded 28 studies that assessed neuropathy as a primary or secondary outcome. Although the use of various scales and scoring systems made comparisons difficult, this analysis identified diseases associated with neuropathy for which approved therapies exist. An important finding is that the symptoms and/or biomarkers of neuropathies were assessed only in a minority of cases. Therefore, further investigation of treatment efficacy on neuropathies in future trials must employ objective, consistent methods such as wearable technologies, motor unit indexes, MRI or sonography imaging, or the use of blood biomarkers associated with consistent nerve conduction studies. |
format | Online Article Text |
id | pubmed-10305260 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-103052602023-06-29 Novel Therapeutic Approaches in Inherited Neuropathies: A Systematic Review Hustinx, Manon Shorrocks, Ann-Marie Servais, Laurent Pharmaceutics Review The management of inherited neuropathies relies mostly on the treatment of symptoms. In recent years, a better understanding of the pathogenic mechanisms that underlie neuropathies has allowed for the development of disease-modifying therapies. Here, we systematically review the therapies that have emerged in this field over the last five years. An updated list of diseases with peripheral neuropathy as a clinical feature was created based on panels of genes used clinically to diagnose inherited neuropathy. This list was extended by an analysis of published data by the authors and verified by two experts. A comprehensive search for studies of human patients suffering from one of the diseases in our list yielded 28 studies that assessed neuropathy as a primary or secondary outcome. Although the use of various scales and scoring systems made comparisons difficult, this analysis identified diseases associated with neuropathy for which approved therapies exist. An important finding is that the symptoms and/or biomarkers of neuropathies were assessed only in a minority of cases. Therefore, further investigation of treatment efficacy on neuropathies in future trials must employ objective, consistent methods such as wearable technologies, motor unit indexes, MRI or sonography imaging, or the use of blood biomarkers associated with consistent nerve conduction studies. MDPI 2023-05-30 /pmc/articles/PMC10305260/ /pubmed/37376074 http://dx.doi.org/10.3390/pharmaceutics15061626 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Hustinx, Manon Shorrocks, Ann-Marie Servais, Laurent Novel Therapeutic Approaches in Inherited Neuropathies: A Systematic Review |
title | Novel Therapeutic Approaches in Inherited Neuropathies: A Systematic Review |
title_full | Novel Therapeutic Approaches in Inherited Neuropathies: A Systematic Review |
title_fullStr | Novel Therapeutic Approaches in Inherited Neuropathies: A Systematic Review |
title_full_unstemmed | Novel Therapeutic Approaches in Inherited Neuropathies: A Systematic Review |
title_short | Novel Therapeutic Approaches in Inherited Neuropathies: A Systematic Review |
title_sort | novel therapeutic approaches in inherited neuropathies: a systematic review |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10305260/ https://www.ncbi.nlm.nih.gov/pubmed/37376074 http://dx.doi.org/10.3390/pharmaceutics15061626 |
work_keys_str_mv | AT hustinxmanon noveltherapeuticapproachesininheritedneuropathiesasystematicreview AT shorrocksannmarie noveltherapeuticapproachesininheritedneuropathiesasystematicreview AT servaislaurent noveltherapeuticapproachesininheritedneuropathiesasystematicreview |